Commercial Supply Bedaquiline Related Intermediates:
3-Benzyl-6-Bbromo-2-Mmethoxyquinoline CAS: 654655-69-3
3-Benzyl-6-Bromo-2-Chloroquinoline CAS: 654655-68-2
3-(Dimethylamino)-1-(Naphthalen-1-yl)propan-1-one Hydrochloride CAS: 5409-58-5
Bedaquiline Fumarate CAS: 845533-86-0
| Chemical Name |
3-Benzyl-6-Bromo-2-Chloroquinoline |
| Synonyms |
6-Bromo-2-Chloro-3-(Phenylmethyl)quinoline; Bedaquiline Impurity B; Bedaquiline Fumarate Impurity 5 |
| CAS Number |
654655-68-2 |
| CAT Number |
RF-PI107 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C₁₆H₁₁BrClN |
| Molecular Weight |
332.62 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Off-White or Light Yellow Powder |
| Purity / Analysis Method |
≥99.0% (HPLC) |
| Melting Point |
100.0~120.0℃ |
| Moisture (K.F) |
≤0.50% |
| Residue on ignition |
≤0.50% |
| Total Impurities |
≤1.00% |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Bedaquiline Fumarate (CAS: 845533-86-0) |
3-Benzyl-6-bromo-2-chloroquinoline (CAS: 654655-68-2) is a main intermediate of Bedaquiline Fumarate (CAS: 845533-86-0). Bedaquiline Fumarate is a diarylquinone drug developed by Janssen Pharmaceutical. The drug, which was approved in 2012 for the treatment of multidrug-resistant tuberculosis (MDR-TB), was developed in partnership with Johnson & Johnson and represents the first new tuberculosis therapy approved in over four decades. Bedaquiline Fumarate used in combination therapy for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of th mycobacteria.